On June 29, the 31^st National Pharmaceutical Industry Information Annual Conference was held in Qingdao, Shandong Province. The National Pharmaceutical Industry Top 100 in 2013 would be unveiled in this event. Based on the main business income, YRPG was again among the Top Three. Xu Haoyu attended the conference. The Top 10 were Guangzhou Pharmaceutical Corporation, Xiuzheng Pharmaceutical Group, Yangtze River Pharmaceutical Group, North China Pharmaceutical Group, China Resources Pharmaceutical Group Limited, WEGO Group, Harbin Pharmaceutical Group, CSPC, Tianjin Pharmaceutical Group, China National Pharmaceutical Group Corporation. YRPG achieved 15.1% growth in 2013 in terms of main income, following the Guangzhou Pharmaceutical Corporation and Xiuzheng Pharmaceutical Group whose business incomes reached 40 billion yuan for the first time, being Top 3 for five consecutive years.
This conference, themed “Reform, Innovation, Past and Future”, attracted over 1,000 governmental leaders, researchers, senior business leaders from the pharmaceutical sector to discuss the innovation of pharmaceutical industry in China, find the path of rejuvenation of pharmaceutical industry and chase the long term goal. The conference, revolving the current policy, research goals, marketing strategies and investment hotspots, was made of major forum, medicine research and development forum, and pharmaceutical marketing strategy forum. Leaders from the government and the sector answered question in their own specialized expertise. During this period, officials from the Ministry of Industry and Information Technology, National Health and Family Planning Commission, State Development and Reform Commission, China Pharmaceutical Administrative Association, expressed their views on the industrial policies and development trends and made in-depth interpretation. Business leaders from China and abroad shared their forecast and response of the pharmaceutical companies to the sector.
Among the top 100 pharmaceutical companies, up to 11 have reached 10 billion size, and the threshold for entering top 100 is 2 billion yuan. The stronger players of the T100 were displaying greater strength. In the distribution of the industry, the chemical preparation companies were predominant, mostly in Jiangsu, Shandong, Beijing, and Zhejiang. As was shown in the ranking, over 70% of companies on the list realized growth both in income and profit.
The conference also released the Best Company of Research and Development Line in 2013 and the Best Value for Investment Company in 2013 (for non-listed company), which reviewed the existing map, growth trend of the pharmaceutical industry in China and provided guidance of its sound development.